Clovis OncologyInc.
MPDL3280A(Clovis Oncology, Inc.)은 Non-small Cell Lung Cancer 표적 치료제로, Non-small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral cortico. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 11.11% (ClinicalTrials.gov NCT04458922). 차별점: novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o.
Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Active
Bispecific antibodies targeting PD-1/PD-L1/VEGF in combination with ch
humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC)
novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o
against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral corticosteroids
immune-mediated adverse events occurred in 17% and 4% of patients, respectively, and there were no grade 4 or 5 events
PD-1 inhibitors had a high
resistance to immunotherapy, primarily due to its low immunogenicity and immune-cold tumor microenvironment
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Clovis OncologyInc.
MPDL3280A(Clovis Oncology, Inc.)은 Non-small Cell Lung Cancer 표적 치료제로, Non-small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral cortico. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 11.11% (ClinicalTrials.gov NCT04458922). 차별점: novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o.
Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Active
Bispecific antibodies targeting PD-1/PD-L1/VEGF in combination with ch
humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC)
novel immunotherapy agents like PD-1 checkpoint inhibitors (anti-PD-1 and anti- PDL-1 antibodies) that improve the capacity o
against the PD-L1/PD-1 pathway, both drugs have similar toxicity profiles related to immune-mediated adverse reactions that can generally be monitored and managed with oral corticosteroids
immune-mediated adverse events occurred in 17% and 4% of patients, respectively, and there were no grade 4 or 5 events
PD-1 inhibitors had a high
resistance to immunotherapy, primarily due to its low immunogenicity and immune-cold tumor microenvironment
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.